GRIT Biotechnology
3 known investors
GRIT Bio (沙砾生物) develops and commercializes next-generation T-cell therapies for oncology and autoimmune disease, including tumor-infiltrating lymphocyte (TIL) therapy, universal allogeneic cell therapy, in vivo CAR-T, and tumor neoantigen vaccines. It builds its own technology platforms for cell screening, gene editing, in vivo delivery, and manufacturing.
AI & Machine LearningBiotechHealthtech
Investors · 3
.jpeg){kind=logo}
Frequently asked questions
- What does GRIT Biotechnology do?
- GRIT Bio (沙砾生物) develops and commercializes next-generation T-cell therapies for oncology and autoimmune disease, including tumor-infiltrating lymphocyte (TIL) therapy, universal allogeneic cell therapy, in vivo CAR-T, and tumor neoantigen vaccines. It builds its own technology platforms for cell screening, gene editing, in vivo delivery, and manufacturing.
- Who are GRIT Biotechnology's investors?
- GRIT Biotechnology's investors include B Capital Group, B4 Capital, Decheng Capital.